China

The National Medical Products Administration (NMPA), formerly known as the China Food and Drug Administration (CFDA), serves as the primary regulatory authority overseeing medical devices, diagnostics, pharmaceuticals, and digital health products in China. The overarching legislative framework is established by the Drug Administration Law (revised 2019), the Regulations on the Supervision and Administration of Medical Devices (revised 2021), and a broad set of associated technical guidelines issued by the NMPA and its affiliated Center for Drug Evaluation (CDE) and Center for Medical Device Evaluation (CMDE). Products are classified according to risk: pharmaceuticals follow a Class I to Class III biologics and chemical drug categorization, while medical devices and diagnostics are tiered from Class I (lowest risk) to Class III (highest risk), with Class III devices requiring the most rigorous pre-market approval. Foreign manufacturers must register products through a China-based legal agent and are subject to Good Manufacturing Practice (GMP) inspections and clinical data requirements.

Key submission requirements include the provision of full technical dossiers aligned with Common Technical Document (CTD) format for pharmaceuticals, and structured technical files for medical devices following NMPA templates that increasingly align with IMDRF guidance. Local clinical trial data conducted in Chinese patient populations have historically been mandatory, though significant reforms under the 2017 to 2023 regulatory modernization agenda have relaxed this requirement for innovative and priority products: overseas clinical data can now be accepted for certain drug and device categories, and China joined the International Council for Harmonisation (ICH) in 2017, accelerating CTD adoption. The NMPA has introduced expedited pathways including Breakthrough Therapy Designation, Priority Review, and Conditional Approval for innovative drugs addressing unmet clinical needs. For digital health and software as a medical device (SaMD), the NMPA issued dedicated guidance in 2021 classifying AI-enabled diagnostic software under the medical device framework. Importers and foreign manufacturers must appoint a registered China legal entity as the local responsible party for post-market surveillance and regulatory correspondence.

Public procurement of health products in China operates through a multi-tiered system coordinated between central and provincial governments. At the national level, the National Healthcare Security Administration (NHSA), established in 2018, oversees the National Reimbursement Drug List (NRDL) and leads centralized volume-based procurement (VBP) programs, commonly referred to as 'group purchasing' or bulk tendering. The National Centralized Drug Procurement Office (NCDPO), operating under the NHSA, conducts national-level VBP rounds that consolidate demand across multiple provinces, driving significant price reductions in exchange for guaranteed market volume. Medical devices, including coronary stents, orthopedic implants, and in vitro diagnostics, have increasingly been brought into centralized procurement rounds since 2021. Provincial and municipal health commissions, working alongside local medical insurance bureaus, conduct supplementary tenders for products not covered by national rounds, resulting in a complex patchwork of overlapping tender cycles that manufacturers must navigate individually.

The private sector plays a substantial and growing role in China's health product market, particularly in Tier 1 and Tier 2 cities where private hospitals, retail pharmacy chains, and direct-to-consumer digital health platforms operate outside the public tender framework. Distributors and commercial agents remain central to private channel access, though the NHSA's two-invoice system reform has streamlined the supply chain by limiting distribution layers for publicly procured products. China does not rely significantly on multilateral donor procurement channels such as UNICEF Supply Division, the Global Fund, or USAID for mainstream health commodities, given its upper-middle-income classification, though international organizations remain active in specific public health programs including HIV, tuberculosis, and maternal health initiatives in lower-resource provinces. Local manufacturing preference policies are prominent: the government actively promotes domestic industry through the Made in China 2025 initiative and preferential procurement policies that favor domestically produced medical devices and pharmaceuticals in public tenders, incentivizing foreign multinationals to establish local manufacturing or joint venture arrangements to remain competitive in the public procurement landscape.